Biotech entity

DMEPOS

Product

All 1 tracked stories fall under one category: pharma. Centers for Medicare & Medicaid Services is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention DMEPOS, all published on March 6, 2026.

Last mentioned: Mar 6, 2026

Entity pulse

Recent coverage · DMEPOS

1 story
7 avg impact
0% positive
100% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.

  • 100% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about DMEPOS

All 1 tracked stories fall under one category: pharma. Centers for Medicare & Medicaid Services is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention DMEPOS, all published on March 6, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering DMEPOS. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Initial Expiration

    The first six-month period ends, at which point CMS may choose to extend the moratorium.

  2. Moratorium Effective

    CMS officially publishes the notice and the nationwide enrollment freeze begins immediately.

  3. Data Review Concludes

    CMS finishes a multi-year review of Medicare enrollment and claims data identifying high-risk trends.

  4. OIG Fraud Warning

    HHS OIG highlights billions in improper DME payments over the previous decade.

Stories mentioning DMEPOS 1

Pharma Negative

CMS Imposes Unprecedented Nationwide Moratorium on DMEPOS Enrollments

The Centers for Medicare & Medicaid Services (CMS) has implemented a six-month nationwide freeze on new Medicare enrollments for seven categories of medical supply companies. This aggressive regulatory move, effective February 27, 2026, aims to curb systemic fraud and billions in improper payments within the DMEPOS sector.

2 sources

DMEPOS is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.